Every Form 4 that enGene Therapeutics Inc. Warrants (ENGNW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ENGNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENGNW filings page.
enGene Therapeutics Inc. director Philip Astley-Sparke received a grant of stock options to acquire 31,000 common shares. The options have an exercise price of $1.75 per share and now represent a total option holding of 31,000 shares.
The option vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders. The options are scheduled to expire on June 16, 2036, if not exercised earlier.
enGene Therapeutics Inc. director Gerald A. Brunk received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and were awarded at no cost.
The options expire on June 16, 2036. According to the disclosure, the option vests fully on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or the company’s 2027 annual meeting of shareholders. Following this grant, Brunk holds options for 31,000 shares directly.
enGene Therapeutics Inc. director Richard M. Glickman received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. Following this grant, he holds 31,000 options directly.
The option award vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders. This is a compensation-related award rather than an open-market purchase or sale.
enGene Therapeutics Inc. director and Interim Chief Medical Officer William Grossman reported receiving two stock option awards. He was granted options covering 200,000 common shares at an exercise price of $1.75 per share, vesting fully on the earlier of the first anniversary of a June 9, 2026 vesting commencement date or the company’s 2027 annual shareholder meeting, for his service as a non-executive director.
He was also granted options on 31,000 common shares at an exercise price of $1.75 per share, vesting in substantially equal monthly installments over 12 months, subject to his continued service as Interim Chief Medical Officer. Both awards expire on June 16, 2036 and are compensation grants rather than open-market purchases or sales.
enGene Therapeutics Inc. director Paul J. Hastings received a grant of stock options for 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. They vest in full on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Michael Thomas Heffernan reported receiving a stock option grant covering 31,000 Common Shares. The option has an exercise price of $1.75 per share, giving him the right to buy shares at that price in the future.
The option was granted as a compensation award and expires on June 16, 2036. It vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Wouter Joustra received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. According to the footnote, the option vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Lota S. Zoth reported receiving a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and were awarded at no cost.
According to the terms, the entire option award vests on the earlier of the first anniversary of the vesting commencement date of June 9, 2026 or the company’s 2027 annual meeting of shareholders. After this grant, Zoth holds 31,000 stock options directly.
enGene Holdings Inc. reported a new equity award to its Chief Scientific Officer, Anthony Tzeyew Cheung. On January 30, 2026, he received a stock option to buy 195,000 common shares at an exercise price of $9.53 per share.
The option vests monthly in substantially equal amounts over 48 months, conditioned on his continued service. After this grant, he beneficially owns 195,000 derivative securities directly, aligning his compensation more closely with the company’s future share performance.
enGene Holdings Inc. reported a new stock option grant to its Chief Legal Officer and Corporate Secretary, Lee G. Giguere. On 01/30/2026, Giguere received a stock option for 195,000 common shares with an exercise price of $9.53, reported as held directly.
The option was granted at no cost and is structured to vest monthly in substantially equal amounts over 48 months, subject to Giguere’s continued service with the company. After this grant, Giguere beneficially owned 195,000 stock options tied to enGene common shares.
enGene Holdings Inc. granted a stock option to Chief Strategy & Ops Officer Alexander Julian Nichols covering 195,000 common shares on January 30, 2026.
The option has an exercise price of $9.53 per share and expires on January 30, 2036. It was granted at no cost to the reporting person and vests in substantially equal monthly installments over 48 months, conditioned on continued service. After this grant, Nichols beneficially owns 195,000 derivative securities directly.
enGene Holdings Inc. reported that Chief Financial Officer D. Ryan Daws received a new stock option grant. On 01/30/2026, he was awarded a Stock Option (Right to Buy) covering 220,000 common shares at an exercise price of $9.53 per share, for no upfront cost.
The option expires on 01/30/2036 and is held directly. It vests monthly in substantially equal amounts over 48 months, conditioned on his continued service with the company, so the right to purchase shares builds gradually over four years rather than all at once.
enGene Holdings Inc. CEO & President Ronald Harold Wilfred Cooper was granted a large stock option award. On 01/30/2026, he received a stock option covering 801,000 common shares at an exercise price of $9.53 per share. The option was reported as held directly.
The option vests monthly in substantially equal amounts over 48 months, conditioned on his continued service. After this grant, he beneficially owned 801,000 derivative securities tied to common shares through this option award.
enGene Holdings Inc. chief technology officer Joan Connolly received a stock option grant for 195,000 common shares on January 30, 2026. The options give her the right to buy these shares at an exercise price of $9.53 per share and expire on January 30, 2036.
The award vests monthly in substantially equal installments over 48 months, contingent on her continued service with the company. This Form 4 reports an incentive-based equity grant, with Connolly directly holding 195,000 derivative securities following the transaction.
enGene Holdings Inc. reported that Chief Regulatory Officer Boyd Matthew Ross received a grant of stock options on January 30, 2026. The award covers 195,000 stock options with an exercise price of $9.53 per common share and no upfront purchase price.
The options vest monthly in substantially equal installments over 48 months, as long as Ross continues his service with the company. Following this grant, Ross beneficially holds 195,000 derivative securities directly in the form of these options.
enGene Holdings Inc. disclosed that Chief Development Officer Jill Buck received a grant of stock options. On January 30, 2026, she was awarded 195,000 stock options with an exercise price of $9.53 per common share. These options were granted at no cost on the grant date and are held directly. The award vests monthly in substantially equal installments over 48 months, contingent on her continued service with the company, and represents her total reported derivative holdings after the transaction.